GNTA, Genenta Science S.p.A. Unsponsored ADR

"Loading Stock Price & Valuation Data ..."

Agentic AI (Pro) Picks for GNTA

Subscribe to iPick.ai (Pro) to use Power Picks, Hidden-Gem Picks, and more.


News Summary: Subscribe

Unlock News Summary by Subscribing to iPick.ai Premium!





Unlock Ask GNTA by Subscribing to iPick.ai Premium!



Stock Chart



Competitors:

(KPTI) Karyopharm Therapeutics Inc


Latest YouTube Video:



CEO:Mr. Pierluigi Paracchi

Headquarter: Via Olgettina No. 58, Milan, MI, Italy, 20132

Industry: Biotechnology,   Investment Track: -,   Employees: 9

Business Summary

Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.